Timothy Wilkin, Weill Cornell Medical College, New York
A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed multiple regimens. Six month data have now yielded dose and toxicity findings and some preliminary recommendations for therapeutic use.
[audio:https://www.audiomedica.com/podcasting/icaac2005/timothy_wilkin.mp3]
AudioMedica News Audio Journal of Infectious Disease: Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy...
AudioMedica News Fire Ants: Purveyors of Pain, or Possible Source of New Antimicrobials? Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
AudioMedica News Latest on Human Papilloma Virus Vaccine for Cervical Cancer Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast...
AudioMedica News Which Macrolide Antibiotics Provide Greatest Barrier to Resistance in Streptococcus pneumoniae? Play Episode Pause Episode...
AudioMedica News Pharmacokinetically Enhanced Amoxicillin and Clavulanate for Drug Resistant Streptococcus Pneumoniae Play Episode Pause Episode...
AudioMedica News New Antiviral Approach for Infectious Mononucleosis - Kissing Disease Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
